Clinical Trials Browser

Enrolling by invitation × tislelizumab × Gastrointestinal × Clear all

NCT06303583 2024-03-12

CRIS

Phase 1/2 Enrolling by invitation

Gastrointestinal

Esophageal Squamous Cell Carcinoma